skip to main content

Denosumab CKD calcium — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardMusculoskeletal TherapeuticsDenosumab CKD calciumGPhC CRA

A woman with eGFR 24 mL/min/1.73 m² has had hypocalcaemia corrected and is now ready for her first denosumab 60 mg dose with calcium and vitamin D supplementation. Which calcium-monitoring plan best reflects the product information?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: D — Check before each dose and within 2 weeks after the initial dose

Calcium should be monitored before each denosumab dose. In patients predisposed to hypocalcaemia, which includes severe renal impairment, the SmPC also recommends calcium monitoring within 2 weeks after the initial dose. Additional measurement is guided by symptoms and individual risk. Correcting pre-existing hypocalcaemia and providing adequate calcium and vitamin D are prerequisites, not substitutes for the specified monitoring.

Reference: Prolia 60 mg solution for injection SmPC: https://www.medicines.org.uk/emc/product/568/smpc